Targeting tumor-promoting CAF subsets, such as G protein-coupled receptor 77 (GPR77)-expressing CAFs, has shown promise in enhancing therapeutic efficacy; combined administration of anti-GPR77 antibodies with chemotherapy improves tumor cell apoptosis and overall treatment response [62]. This evidence concerns the gene C5AR2 and neoplasm.